Lanshoeft Christian, Heudi Olivier, Leuthold Luc Alexis, Schlotterbeck Götz, Elbast Walid, Picard Franck, Kretz Olivier
Novartis Pharma AG, DMPK/Bioanalytics, Forum 1 Novartis Campus, 4056, Basel, Switzerland.
Anal Bioanal Chem. 2014 Sep;406(22):5413-23. doi: 10.1007/s00216-014-7966-6. Epub 2014 Jun 24.
A sensitive and ultra-fast method utilizing the laser diode thermal desorption ion source using atmospheric pressure chemical ionization coupled to tandem mass spectrometry (LDTD-APCI-MS/MS) was developed for the quantitative analysis of BKM120, an investigational anticancer drug in human plasma. Samples originating from protein precipitation (PP) followed by salting-out assisted liquid-liquid extraction (SALLE) were spotted onto the LazWell™ plate prior to their thermal desorption and detection by tandem mass spectrometry in positive mode. The validated method described in this paper presents a high absolute extraction recovery (>90 %) for BKM120 and its internal standard (ISTD) [D8]BKM120, with precision and accuracy meeting the acceptance criteria. Standard curves were linear over the range of 5.00 to 2000 ng mL(-1) with a coefficient of determination (R (2)) >0.995. The method specificity was demonstrated in six different batches of human plasma. Intra- and inter-run precision as well as accuracy within ±20 % at the lower limit of quantification (LLOQ) and ±15 % (other levels) were achieved during a three-run validation for quality control (QC) samples. The post-preparative stability on the LazWell™ plate at room temperature was 72 h and a 200-fold dilution of spiked samples was demonstrated. The method was applied successfully to three clinical studies (n = 847) and cross-checked with the validated LC-ESI-MS/MS reference method. The sample analysis run time was 10 s as compared to 4.5 min for the current validated LC-ESI-MS/MS method. The resultant data were in agreement with the results obtained using the validated reference LC-ESI-MS/MS assay and the same pharmacokinetic (PK) parameters were calculated for both analytical assays. This work demonstrates that LDTD-APCI-MS/MS is a reliable method for the ultra-fast quantitative analysis of BKM120 which can be used to speed-up and support its bioanalysis in the frame of the clinical trials.
开发了一种灵敏且超快速的方法,该方法利用激光二极管热解吸离子源,结合大气压化学电离与串联质谱(LDTD-APCI-MS/MS),用于定量分析人血浆中的研究性抗癌药物BKM120。源自蛋白质沉淀(PP)随后进行盐析辅助液液萃取(SALLE)的样品,在热解吸并通过正模式串联质谱检测之前,点样到LazWell™板上。本文所述的经过验证的方法对BKM120及其内标(ISTD)[D8]BKM120具有较高的绝对提取回收率(>90%),精密度和准确度符合验收标准。标准曲线在5.00至2000 ng mL(-1)范围内呈线性,决定系数(R (2))>0.995。该方法的特异性在六批不同的人血浆中得到了验证。在对质量控制(QC)样品进行的三次运行验证期间,在定量下限(LLOQ)处实现了批内和批间精密度以及准确度在±20%以内,在其他水平处实现了±15%以内。在室温下,LazWell™板上制备后的稳定性为72小时,并且证明加标样品可进行200倍稀释。该方法成功应用于三项临床研究(n = 847),并与经过验证的LC-ESI-MS/MS参考方法进行了交叉核对。与当前经过验证的LC-ESI-MS/MS方法的4.5分钟相比,样品分析运行时间为10秒。所得数据与使用经过验证的参考LC-ESI-MS/MS测定法获得的结果一致,并且两种分析方法计算出的药代动力学(PK)参数相同。这项工作表明,LDTD-APCI-MS/MS是一种用于BKM120超快速定量分析的可靠方法,可用于在临床试验框架内加速并支持其生物分析。